Patient-specific neoantigen peptide-major histocompatibility complex (Neoantigen-pMHC)

Patient-specific neoantigen peptide-major histocompatibility complexes (pMHCs) are unique molecular targets formed when somatic mutations in a tumor's genome result in novel, non-self proteins. These mutant proteins are processed into short peptides and presented on the tumor cell surface by Major Histocompatibility Complex (MHC) molecules, also known as Human Leukocyte Antigens (HLA) in humans (Source: Nature Reviews Cancer, 2021). Because these neoantigens are entirely absent from healthy tissues, they serve as highly specific targets for the immune system, theoretically eliminating the 'off-target, on-tumor' toxicities associated with traditional tumor-associated antigens (Source: NIH National Cancer Institute). Therapeutic strategies targeting these complexes include personalized mRNA or peptide vaccines designed to prime the patient's own T-cells, as well as adoptive cell therapies like TCR-engineered T-cells (TCR-T) that are programmed to recognize specific pMHC sequences (Source: PubMed, PMID: 31048564). The clinical utility of these targets depends heavily on advanced bioinformatics for neoantigen prediction and the patient's individual HLA profile (Source: Frontiers in Immunology, 2020). Despite their promise, challenges remain regarding the heterogeneity of neoantigen expression within a single tumor and the potential for tumor escape through the loss of MHC expression (Source: Journal of Hematology & Oncology, 2021).

Other names

Tumor-specific neoantigen (TSA)Neoepitope-MHC complexMutant peptide-MHC complexPersonalized neoantigenNeoantigen-HLA complex

Induction of de novo T-cell responses or expansion of existing neoantigen-specific T-cells; direct targeting of the complex via engineered T-cell receptors (TCR-T) or bispecific antibodies to induce tumor cell lysis.